Gilead Sciences, Inc. (BMV:GILD)

Mexico flag Mexico · Delayed Price · Currency is MXN
2,605.83
+9.54 (0.37%)
Last updated: Feb 9, 2026, 9:09 AM CST
Market Cap3.23T +37.9%
Revenue (ttm)533.52B +2.8%
Net Income148.76B +6,336.5%
EPS117.81 +6,514.1%
Shares Outn/a
PE Ratio21.74
Forward PE18.59
Dividend59.68 (2.29%)
Ex-Dividend DateDec 15, 2025
Volume666
Average Volume1,848
Open2,605.83
Previous Close2,596.29
Day's Range2,605.83 - 2,605.83
52-Week Range1,874.30 - 2,605.83
Beta0.35
RSI74.66
Earnings DateFeb 10, 2026

About Gilead Sciences

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy p... [Read more]

Sector Healthcare
Founded 1987
Employees 17,600
Stock Exchange Mexican Stock Exchange
Ticker Symbol GILD
Full Company Profile

Financial Performance

In 2024, Gilead Sciences's revenue was $28.75 billion, an increase of 6.04% compared to the previous year's $27.12 billion. Earnings were $480.00 million, a decrease of -91.53%.

Financial numbers in USD Financial Statements